Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals (MXC) completes a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma
- The study was undertaken between 2019 and 2022, initially using a formulation that included THC but was later replaced with cannabigerol (CBG)
- Over 5800 cell tests were collected from 18 patients to determine the most effective concentrations and ratios of cannabidiol (CBD) and CBG in treatment
- The results demonstrated the efficacy of cannabinoids in the treatment of glioblastoma and determined the most effective CBD:CBG ratio
- MGC Pharma ends the day 35.3 per cent in the green with shares trading at 2.3 cents
MGC Pharmaceuticals (MXC) has completed a successful in-vitro preclinical research study in the use of cannabinoids to treat glioblastoma.
Glioblastoma is a fast-growing and aggressive brain tumour that can affect the brain and spine. Current treatments include radiosurgery, craniotomy, chemotherapy and radiation.
The study was undertaken between 2019 and 2022, initially using a formulation that included tetrahydrocannabinol (THC) but was later replaced with cannabigerol (CBG).
Over 5800 cell tests were collected from 18 patients to determine the most effective concentrations and ratios of cannabidiol (CBD) and CBG in treatment.
The results demonstrated the efficacy of cannabinoids in the treatment of glioblastoma and determined the most effective CBD:CBG ratio.
MGC Pharma is also undertaking studies with Graft Polymer UK PLC for the use of a base formulation nano delivery system to improve the bioavailability of the active compounds using a non-invasive drug administration process.
The studies examined the toxicity of the base emulation in order to confirm its safety profile for potential use in future clinical research.
The studies also examined the effect of adding a widely used chemotherapy agent to the treatment to determine the effect on its efficacy with the outcome demonstrating the addition had no effects to cell apoptosis (programmed cell death).
This suggests that MGC Pharma’s cannabinoid can potentially be used in further studies to determine the efficacy of its glioblastoma treatment in a clinical trial.
“The results of this trial are enormously exciting both for the company, and for the treatment of fatal cancerous tumours,” Co-Founder and Managing Director Roby Zomer said.
“MGC Pharma’s research has demonstrated the effect of naturally derived cannabinoid products on stage IV brain tumours without the use of toxic chemotherapy components.”
MGC Pharma has ended the day 35.3 per cent in the green with shares trading at 2.3 cents.
